- Home
- CJMB vs ATHA Comparison
CJMB vs ATHA Comparison
Compare CJMB & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJMB
- ATHA
- Stock Information
- Founded
- CJMB 2007
- ATHA 2011
- Country
- CJMB United States
- ATHA United States
- Employees
- CJMB N/A
- ATHA N/A
- Industry
- CJMB
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- CJMB
- ATHA Health Care
- Exchange
- CJMB NYSE
- ATHA Nasdaq
- Market Cap
- CJMB 18.8M
- ATHA 21.0M
- IPO Year
- CJMB 2025
- ATHA 2020
- Fundamental
- Price
- CJMB $5.54
- ATHA $0.43
- Analyst Decision
- CJMB
- ATHA Buy
- Analyst Count
- CJMB 0
- ATHA 4
- Target Price
- CJMB N/A
- ATHA $11.25
- AVG Volume (30 Days)
- CJMB 891.7K
- ATHA 210.5K
- Earning Date
- CJMB 01-01-0001
- ATHA 03-04-2025
- Dividend Yield
- CJMB N/A
- ATHA N/A
- EPS Growth
- CJMB N/A
- ATHA N/A
- EPS
- CJMB N/A
- ATHA N/A
- Revenue
- CJMB $6,884,783.00
- ATHA N/A
- Revenue This Year
- CJMB N/A
- ATHA N/A
- Revenue Next Year
- CJMB N/A
- ATHA N/A
- P/E Ratio
- CJMB N/A
- ATHA N/A
- Revenue Growth
- CJMB N/A
- ATHA N/A
- 52 Week Low
- CJMB $3.38
- ATHA $0.41
- 52 Week High
- CJMB $7.76
- ATHA $4.21
- Technical
- Relative Strength Index (RSI)
- CJMB N/A
- ATHA 34.62
- Support Level
- CJMB N/A
- ATHA $0.42
- Resistance Level
- CJMB N/A
- ATHA $0.46
- Average True Range (ATR)
- CJMB 0.00
- ATHA 0.04
- MACD
- CJMB 0.00
- ATHA -0.00
- Stochastic Oscillator
- CJMB 0.00
- ATHA 10.85
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.